Dueling for Duals: Why the Poorest Medicare Recipients Should be Pharma's Top Priority in 2006
This article was originally published in RPM Report
The transfer of the poorest Medicare recipients to Part D means big changes in a critical submarket for pharma. If all goes well, it should pay off in a de facto price increase for some of the biggest industry blockbusters.
You may also be interested in...
Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.
Pharmaceutical manufacturers interested in maximizing their market share under the new Medicare drug benefit in 2006 should focus on four insurers likely to take the lion's share of enrollment. Dozens of plans are entering the market, but UnitedHealth Group, Wellpoint, Humana and Wellcare will start with a big edge in enrollment as of January 1. An analysis by The RPM Report explains why.
A two-day workshop on potential biomarkers in NASH provided a forum for US FDA officials to offer implicit reassurance to drug developers: the agency stands behind its guidance on Accelerated Approval for the liver disease, despite the rejection of the first application seeking to use that approach.